Skip to content

Dandruff treatment with unani formulation

Therapeutic evaluation of a topical unani formulation in the treatment of Hazaz (Pityriasis capitis): A randomizes open label pilot controlled trial. - Nill

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/081624
Enrollment
24
Registered
2025-03-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L210- Seborrhea capitis

Interventions

Intervention1: Ab-i Chuqandar (Beta Vugaris) mixed with Bura Armani (Borax): Form- Freshly obtain juice of Chuqandar (Beta Vulgaris) mixed with Bura Armani (borax) Route of Application- Topical on Hea

Sponsors

Central Council for Research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients of age group of 15 to 65 years with a clinical diagnosis of adherent dandruff of the scalp. 2 Must have active adherent dandruff of the scalp 3 Investigators global assessment (IGA) for pruritis score of at least 1. 4 Understand and willing to sign written informed consent in case of adults and written parental assent in case of children wherever applicable.

Exclusion criteria

Exclusion criteria: 1 Pregnant or lactating women by history. 2 History of overt bacterial, viral or fungal infection of the head/neck 3 Patients with history or presence of any serious disease including immunological conditions like HIV, current malignancies, diabetes mellitus. Hypertension, etc. 4History or presence of compromising dermatosis elsewhere on the skin; 5 Patients with damaged skin of scalp 6 Patients with any skin condition e.g., psoriasis, acne, atopic dermatitis; 7 Patients who had used within 1 month prior to baseline any topical and systemic treatment for scalp diseases.

Design outcomes

Primary

MeasureTime frame
Adherent scalp flaking score (ASFS)Timepoint: Baseline 5th day 9th day and 14th day

Secondary

MeasureTime frame
1 IGA for pruritus on 4 point scale 2 Dermatology life quality index (DLQI)Timepoint: AT Baseline & 14th day

Countries

India

Contacts

Public ContactDr Shaikh Nisar Ahmed Abbas

Luqman Unani Medical College Hospital and Research Centre

drjuveriya10@gmail.com7406810517

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026